September 2024

Publication comes ahead of the FDA Advisory Panel Meeting for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer scheduled for November 7, 202496.3% recurrence free rate for women treated with ProSense® cryoablation and endocrine therapy; 100% of patients and treating physi

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: